Work

Aducanumab produced a clinically meaningful benefit in association with amyloid lowering

Year: 2021

Type: article

Source: Alzheimer s Research & Therapy

DOI: 10.1186/s13195-021-00838-z

Authors: Jeffrey Cummings, Paul Aisen, Cynthia Lemere, Alireza Atri, Marwan Sabbagh, Stephen Salloway

Institutions: University of Nevada, Las Vegas, University of Southern California, Brigham and Women's Hospital, Harvard University, Banner Health, Banner Sun Health Research Institute, Cleveland Clinic, Lou Ruvo Brain Institute, Brown University, Butler Hospital

Language: English

Topic: Alzheimer's disease research and treatments

Subfield: Cellular and Molecular Neuroscience

Field: Neuroscience

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,490

Funders: National Institute on Aging, National Institute of General Medical Sciences, National Institute of Neurological Disorders and Stroke

Awards: Chronic Traumatic Encephalopathy: Detection, Diagnosis, Course, and Risk Factors, Global Alzheimer's Platform Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease, Nevada Exploratory Alzheimer's Disease Research Center (NVEADRC), Renewal of Centers of Biomedical Research Excellence (COBRE) (Phase 2) CNTN - Resubmission, Alzheimer's Clinical Trial InnOvatioN (ACTION) Initiative

OpenAlex ID: W3161140821

FWCI: 19.03

Cites: 19

Cited by: 234

Related to: 10